Oral immunization with Lactococcus lactis secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model

Microbial Cell Factories

Volumn 12, Issue 1, 2013, Pages

  Asensi, Giselli Fernandes ^a   de Sales, Nathalia Ferrari Fonseca ^a   Dutra, Fabiano Ferreira ^a   Feijó, Daniel Ferreira ^a   Bozza, Marcelo Torres ^a   Ulrich, Robert G ^b   Miyoshi, Anderson ^c   de Morais, Katia ^c   Azevedo, Vasco Ariston de Carvalho ^c   Silva, Joab Trajano ^a   Loir, Yves Le ^d,e   Paschoalin, Vânia Margaret Flosi ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d UMR1253   (France)

^e AGROCAMPUS OUEST   (France)

Author keywords

Intestinal IgA antibodies; Lactococcus lactis; Live vaccine; Oral mice immunization; Recombinant enterotoxin B (rSEB); Serum IgG antibodies; Staphylococcus aureus

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NCDO 2118; PROBIOTIC AGENT; STAPHYLOCOCCUS ENTEROTOXIN B; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBODY TITER; ARTICLE; CYTOPLASM; DRUG EFFICACY; FECES; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; LACTOCOCCUS LACTIS; MOUSE; NONHUMAN; SPLEEN; STAPHYLOCOCCUS INFECTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES; ENTEROTOXINS; LACTOCOCCUS LACTIS; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

ANIMALIA; BACTERIA (MICROORGANISMS); LACTOCOCCUS LACTIS; MURINAE; MUS; STAPHYLOCOCCUS AUREUS;

EID: 84875854906     PISSN: None     EISSN: 14752859     Source Type: Journal    
DOI: 10.1186/1475-2859-12-32     Document Type: Article

References (40)

1. Casey AL, Lambert PA, Elliott TS. Staphylococci. Int J Antimicrob Agents 2007, 29:23-32.
2. Stiles BG, Garza AR, Ulrich RG, Boles JW. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect Immun 2001, 69:2031-2036. 10.1128/IAI.69.4.2031-2036.2001, 98127, 11254555.
3. Trilla A, Miro JM. Identifying high risk patients for Staphylococcus aureus infections: skin and soft tissue infections. J Chemother 1995, 7:37-43.
4. Swaminathan S, Furey W, Pletcher J, Sax M. Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature 1992, 359:801-806. 10.1038/359801a0, 1436058.
5. Madsen JM. Toxins as weapons of mass destruction: a comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med 2001, 21:593-605.
6. Ahanotu E, Alvelo-Ceron D, Ravita T, Gaunt E. Staphylococcal enterotoxin b as a biological weapon: recognition, management, and surveillance of staphylococcal enterotoxin. Appl Biosafety 2006, 11:120-126.
7. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997, 278:399-411. 10.1001/jama.1997.03550050061035, 9244332.
8. Leggiadro RJ. The threat of biological terrorism: a public health and infection control reality. Infect Control Hosp Epidemiol 2000, 21:53-56. 10.1086/501700, 10656359.
9. Bavari S, Dyas B, Ulrich RG. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin. Am J Infect Dis 1996, 174:338-345.
10. Ulrich RG, Olson MA, Bavari S. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 1998, 16:1857-1864. 10.1016/S0264-410X(98)00176-5, 9795392.
11. Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Torres E, Dyas B, Ulrich RG, Bavari S. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol 2003, 108:51-59. 10.1016/S1521-6616(03)00066-4, 12865071.
12. Bermúdez-Humarán LG, Kharrat P, Chatel J-M, Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNAvaccines. Microbial Cell Factories 2011, 10:1-10. 10.1186/1475-2859-10-1, 3022669, 21211066.
13. Pouwels PH, Leer RJ, Shaw M, Heijne den Bak-Glashouwer MJ, Tielen FD, Smit E, Martinez B, Jore J, Conway PL. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. Int J Food Microbiol 1998, 41:155-167. 10.1016/S0168-1605(98)00048-8, 9704864.
14. Le Loir Y, Azevedo V, Oliveira SC, Freitas DA, Miyoshi A, Bermúdez-Humarán LG, Nouaille S, Ribeiro LA, Leclercq S, Gabriel JE, Guimaraes VD, Oliveira MN, Charlier C, Michel Gautier M, Philippe Langella P. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microbial Cell Factories 2005, 4:2. 10.1186/1475-2859-4-2, 545053, 15631634.
15. Bolotin A, Wincker P, Mauger S, Jaillon O, Malarne K, Weissenbach J, Dusko Erlich S, Sorokin A. The Complete Genome Sequence of the Lactic Acid Bacterium Lactococcus lactis ssp. lactis IL1403. Genome Res 2001, 11:731-753. 10.1101/gr.GR-1697R, 311110, 11337471.
16. Frossard CP, Steidler L, Eigenmann PA. Oral administration of an IL-10-secreting Lactococcus lactis strain prevents food-induced IgE sensitization. J Allergy Clin Immunol 2007, 119:952-959. 10.1016/j.jaci.2006.12.615, 17316776.
17. Medina M, Villena J, Salva S, Vintiñi E, Langella P. Nasal administration of Lactococcus lactis improves local and systemic immune responses against Streptococcus pneumoniae. Microbiol Immunol 2008, 52:399-409. 10.1111/j.1348-0421.2008.00050.x, 18667039.
18. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat Rev Microbiol 2008, 6:349-362. 10.1038/nrmicro1840, 18345021.
19. Le Loir Y, Azevedo V, Oliveira SC, Freitas DA, Miyoshi A, Bermúdez-Humarán LG, Nouaille S, Ribeiro LA, Leclercq S, Gabriel JE, Guimaraes VD, Oliveira MN, Charlier C, Gautier M, Langella P. Protein secretion in Lactococcus lactis: an efficient way to increase the overall heterologous protein production. Microb Cell Fact 2005, 4:2. 10.1186/1475-2859-4-2, 545053, 15631634.
20. Bermúdez-Humarán LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum Vacc 2009, 5:264-267.
21. Streatfield S. Mucosal immunization using plant-based oral vaccines. Methods 2006, 38:150-157. 10.1016/j.ymeth.2005.09.013, 16431131.
22. van Asseldonk M, Rutten G, Oteman M, Siezen RJ, de Vos WM, Simons G. Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene 1990, 95:155-160. 10.1016/0378-1119(90)90428-T, 2123812.
23. Le Loir Y, Gruss A, Ehrlich SD, Langella P. Direct screening of recombinants in Gram-positive bacteria using the secreted staphylococcal nuclease as a reporter. J Bacteriol 1994, 176:5135-5139. 196356, 8051029.
24. Que YA, François P, Haefliger JA, Entenza JM, Vaudaux P, Moreillon P. Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis. Infect Immun 2001, 69:6296-6302. 10.1128/IAI.69.10.6296-6302.2001, 98764, 11553573.
25. Clarke SR, Walsh EJ, Dufrêne YF, Foster TJ, Foster SJ. Iron-regulated surface determinant protein A mediates adhesion of Staphylococcus aureus to human corneocyte envelope proteins. Infect Immun 2009, 77:2408-2416. 10.1128/IAI.01304-08, 2687344, 19307218.
26. Innocentin S, Guimarães V, Miyoshi A, Azevedo V, Langella P, Chatel JM, Lefèvre F. Lactococcus lactis expressing either Staphylococcus aureus fibronectin-binding protein A or Listeria monocytogenes internalin A can efficiently internalize and deliver DNA in human epithelial cells. Appl Environ Microbiol 2009, 75:4870-4878. 10.1128/AEM.00825-09, 2708419, 19482952.
27. Harro CD, Bett RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, Kartsonis NA. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): Results of two Phase I studies. Vaccine 2012, 30:1729-1736. 10.1016/j.vaccine.2011.12.045, 22192849.
28. Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect Dis Clin N Am 2009, 23:153-171.
29. Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001, 108:107-110.
30. Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 2009, 27:3276-3280. 10.1016/j.vaccine.2009.01.062, 19200819.
31. Chang BS, Moon JS, Kang HM, Kim Y-I, Lee H-K, Kim J-D, Lee B-S, Koo HC, Park YH. Protective effects of recombinant staphylococcal enterotoxin type C mutant vaccine against experimental bovine infection by a strain of Staphylococcus aureus isolated from subclinical mastitis in dairy cattle. Vaccine 2008, 26:2081-2091. 10.1016/j.vaccine.2008.02.043, 18387721.
32. Castagliuolo I, Piccinini R, Beggiao E, Palù G, Mengoli C, Ditadi F, Vicenzoni G, Zecconi A. Mucosal genetic immunization against four adhesins protects against Staphylococcus aureus-induced mastitis in mice. Vaccine 2006, 24:4393-4402. 10.1016/j.vaccine.2006.02.055, 16580097.
33. Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect Immun 2008, 76:5738-5744. 10.1128/IAI.00874-08, 2583566, 18809660.
34. Reveneau N, Geoffroy MC, Locht C, Chagnaud P, Mercenier A. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 2002, 20:1769-1777. 10.1016/S0264-410X(02)00027-0, 11906764.
35. Pocsfalvi G, Cacace G, Cuccurullo M, Serluca G, Sorrentino A, Schlosser G, Blaiotta G, Malorni A. Proteomic analysis of exoproteins expressed by enterotoxigenic Staphylococcus aureus strains. Proteomics 2008, 8:2462-2476. 10.1002/pmic.200700965, 18563740.
36. Vojtov N, Ross HF, Novick RP. Global repression of exotoxin synthesis by staphylococcal superantigens. Proc Natl Acad Sci U S A 2002, 99:10102-10107. 10.1073/pnas.152152499, 126631, 12110733.
37. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual 1989, New York: Cold Spring Harbor.
38. Langella P, Le Loir Y, Ehrlich SD, Gruss A. Efficient plasmid mobilization by pIP501 in Lactococcus lactis subsp. lactis. J Bacteriol 1993, 175:5806-5813. 206659, 8376328.
39. Le Loir Y, Gruss A, Ehrlich SD, Langella P. A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol 1998, 180:1895-1903. 107105, 9537390.
40. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685. 10.1038/227680a0, 5432063.